| Literature DB >> 35237434 |
Kayle S Shapero1, Varidhi Nauriyal2, Christina Megli3, Kathryn Berlacher1, Sami El-Dalati4.
Abstract
INTRODUCTION: The incidence of infective endocarditis (IE) in pregnancy is rare and has been increasing during the opioid epidemic. IE in pregnancy is associated with high rates of maternal and fetal morbidity and mortality. Multidisciplinary endocarditis teams for management of IE have been shown to reduce in-hospital and 1-year mortality. We present a single-center experience managing IE in pregnancy utilizing a multidisciplinary endocarditis team.Entities:
Keywords: endocarditis; injection drug use; multidisciplinary team; pregnancy
Year: 2022 PMID: 35237434 PMCID: PMC8883368 DOI: 10.1177/20499361221080644
Source DB: PubMed Journal: Ther Adv Infect Dis ISSN: 2049-9361
Demographic data for pregnant patients with infectious endocarditis managed by the multidisciplinary endocarditis team at the University of Pittsburgh Medical Center.
| Variable | Mean | Median | Range | |
|---|---|---|---|---|
| Average age at delivery | 29.3 years | 28 years | 26–37 years | |
| Race | ||||
| Black | 1 (17) | |||
| White | 5 (83) | |||
| Distance from tertiary care site | 46 miles | 50 miles | 5–75 miles | |
| Medicaid/Medicare | 6 (100) | |||
| Gestational age at first obstetrics visit | 10.9 weeks | 9.3 weeks | 6 – 17.5weeks | |
| Gestational age at diagnosis | 22.6 weeks | 26 weeks | 6–34 weeks | |
| Gravida-multiparous | 6 (100) | G4 | G4 | G2 – G5 |
| Incarceration at the time of pregnancy/prior to diagnosis | 1 (17) | |||
| Hypertension | 0 (0) | |||
| Coronary artery disease | 0 (0) | |||
| Chronic kidney disease | 0 (0) | |||
| Obesity | 1 (17) | |||
| Hepatitis C antibody positive | 5 (83) | |||
| HIV infection | 0 (0) | |||
| Rheumatic fever | 0 (0) | |||
| Thyroid disease | 0 (0) | |||
| Asthma | 0 (0) | |||
| Tobacco use | 3 (50) | |||
| Injection drug use | 6 (100) | |||
| Mental health disorder | 6 (100) | |||
| Bicuspid aortic valv | 1 (17) | |||
| Prosthetic valve | 0 (0) | |||
| Intracardiac devices | 0 (0) | |||
| Congenital heart disease | 0 (0) | |||
| History of endocarditis | 2 (33) | |||
| Medication assisted treatment of opioid use disorder | 3 (50) | |||
HIV, human immunodeficiency virus.
Description of endocarditis and modality of medical therapy for pregnant patients with endocarditis.
| Variable | Mean | Median | Range | |
|---|---|---|---|---|
| Valve location | ||||
| Tricuspid | 4 (67) | |||
| Mitral | 2 (33) | |||
| Pulmonic | 1 (17) | |||
| No vegetation visualized | ||||
| Duration of bacteremia | 5.8 days | 5.5 days | 2–12 days | |
| Organism | ||||
| MSSA | 6 (100) | |||
| Average vegetation size | 1.9 x 1.2 cm | 1.7 x 1 cm | 0.5 cm x 0.7 cm to 2 cm x 2 cm | |
| Suspected source | ||||
| Injection-drug use | 6 (100) | |||
| Embolic phenomenon | ||||
| Stroke | 3 (50) | |||
| Pulmonic septic emboli | 5 (87) | |||
| Other septic emboli | 3 (50) | |||
| Mechanical ventilation | 5 (83) | |||
| Regurgitation severity | ||||
| Mild | 1 (17) | |||
| Moderate | 2 (33) | |||
| Moderate-severe | 2 (33) | |||
| Severe | 1 (17) | |||
| Heart failure | 1 (17) | |||
| Average ejection fraction | 58% | 55% | 52%–62% | |
| Arrhythmia | 1 (17) | |||
| ICU admission | 5 (83) | |||
| Average ICU length of stay | 7 days | 7 days | 2–15 days | |
| Surgical Indication | ||||
| Heart failure from valve dysfunction | 1 (17) | |||
| Persistent bacteremia | 3 (50) | |||
| Abscess/heart block/destructive penetrating lesion | 0 (0) | |||
| Recurrent emboli despite antibiotic therapy | 4 (67) | |||
| Large vegetation (>1.0–1.5 cm) | 5 (84) | |||
| Antimicrobial agents | ||||
| Oxacillin | 5 (83) | |||
| Cefazolin | 1 (17) | |||
| Combination antibiotic therapy | 3 (50) | |||
| Transition to oral antibiotics | 1 (17) | |||
| Duration of antimicrobial treatment | 42 days | 42 days | 28–56 days | |
| Successful completion of antibiotic therapy | 5 (83) | |||
| Addiction medicine consult | 6 (100) | |||
| New medication for opioid use disorder started during admission | 5 (83) | |||
ICU, Intensive care unit; MSSA, Methicillin-susceptible Staphylococcus aureus.
Mortality, surgical and post-operative outcomes for pregnant patients with endocarditis managed by the multidisciplinary endocarditis team.
| Outcome | Mean | Median | Range | |
|---|---|---|---|---|
| In hospital mortality | 0 (0) | |||
| 90-day mortality | 0 (0) | |||
| Average time from admission to cardiac surgery consultation | 6.8 days | 7 days | 2–15 days | |
| Surgical intervention details | ||||
| Valve replacement | 4 (67) | 16.5 days | ||
| Valve repair | 0 (0) | |||
| Other (PFO closure) | 1 (0) | |||
| Time from admission to intervention | ||||
| Average cardiopulmonary bypass time | ||||
| CIED required | 1 (17) | |||
| Intracranial hemorrhage post operatively | 1 (17) | |||
| Average length of stay | 30 days | 28 days | 17–46 days | |
| 30-day readmission | 2 (33) | |||
CIED, cardiac implantable electronic device; PFO, patent foramen ovale.
Post-discharge outcomes, including rates of follow-up, relapsed injection drug use and recurrent endocarditis for pregnant patients with endocarditis managed by the multidisciplinary endocarditis team.
| Outcome | |
|---|---|
| Total number of follow up visits | |
| Emergency department visits | 7 |
| Obstetrics visits | 2 |
| Cardiology visits | 2 |
| Cardiac surgery visits | 4 |
| Infectious disease visits | 2 |
| Primary care visits | 8 |
| Contraception use | 1 (17) |
| 30-day readmission | 2 (33) |
| Recurrent endocarditis | 2 (33) |
| Relapsed injection drug use | 3 (50) |
Obstetric outcomes for pregnant patients with endocarditis managed by the multidisciplinary endocarditis team.
| Outcome | Mean | Median | Range | |
|---|---|---|---|---|
| Mode of delivery | ||||
| Spontaneous vaginal delivery | 3 (50) | |||
| C-section | 1 (17) | |||
| Unknown | 1 (17) | |||
| Indication for C-section | Fetal bradycardia | |||
| Post-partum hemorrhage | 0 (0) | |||
| Induction of labor | 0 (0) | |||
| Stillbirth | 0 (0) | |||
| Miscarriage/IUFD | 1 (17) | |||
| Elective termination | 0 (0) | |||
| Average gestational age at birth | 32 weeks | 31 weeks | 28–39 weeks | |
| Average gestational age at miscarriage | 10 weeks | 10 weeks | n/a | |
IUFD, Intrauterine fetal demise.
Fetal outcomes for babies born to mothers with infectious endocarditis whose care was managed by the multidisciplinary endocarditis team.
| Outcome | Mean | Median | Range | |
|---|---|---|---|---|
| Mortality | 1 (17) | |||
| Average Birth weight | 1816 g | 1083 g | 1050–3316 g | |
| Average Apgar Scores (1, 5 minutes) | (2.3, 5.7) | (1, 7) | (1, 2)–(5, 7) | |
| Corticosteroids administered | 1 (17) | |||
| Congenital abnormalities | 0 (0) | |||
| Respiratory distress syndrome | 2 (33) | |||
| Neonatal abstinence syndrome | 1 (17) | |||
| Early or late onset sepsis | 1 (17) | |||
| Interventricular hemorrhage | 2 (33) | |||
| Neonatal Intensive Care Unit stay required | 3 (50) | |||
| Average NICU length of stay | 44.3 days | 46 days | 17–70 days | |
| Breastfeeding | 0 (0) |
Potential benefits of a multidisciplinary endocarditis team on the care of pregnant patients with endocarditis.
| Discipline | Potential Benefit |
|---|---|
| Cardiac surgery | Increased access to valve surgery |
| Obstetrics | Decreased maternal mortality |
| Infectious diseases | Selection for oral antibiotics |
| Addiction medicine | Increased access to medication for opioid use disorder |
| Hospital medicine | Decreased patient directed discharges |